923 Spam-Free Article(s) Found
Article Searches
Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy http://www.zacks.com/stock/news/300249/q1-earnings-surprise-well-in-cards-healthcare-etfs-to-buy?cid=CS-ZC-FT-300249 Apr 23, 2018 - Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.
Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings? http://www.zacks.com/stock/news/300237/is-a-beat-in-store-for-bristol-myers-bmy-in-q1-earnings?cid=CS-ZC-FT-300237 Apr 23, 2018 - Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.
How To Retire At 65 With Only Half A Million https://seekingalpha.com/article/4164602-retire-65-half-million?source=feed Apr 23, 2018 - Seeking Alpha helps retirees and future retirees face current issues.Today, I will be going over investor priorities and fears when planning for the future.Dividend investing is a great source of inco
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised) http://www.zacks.com/stock/news/300243/fda-nods-to-astrazenecas-tagrisso-for-first-line-nsclc-revised?cid=CS-ZC-FT-300243 Apr 23, 2018 - Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.
The No BS Plan Report, Week 10: Where The Reliable Falter https://seekingalpha.com/article/4164650-bs-plan-report-week-10-reliable-falter?source=feed_sector_healthcare Apr 22, 2018 - Week 10 sees some more decline, including in the blue-chip Bristol-Myers.Some movement was observed in our midcaps.Mostly the stocks continue to hold, too high or low to reach targets, but this could
Rounds Report: Solid Biosciences Is Making A Comeback While Improving FDA Policies To Favor Nektar https://seekingalpha.com/article/4164648-rounds-report-solid-biosciences-making-comeback-improving-fda-policies-favor-nektar?source=feed_all_articles Apr 22, 2018 - Solid Biosciences rallied aggressively, as the company is experiencing increasing industry tailwinds. The temporary concerns re gene editing and therapy are now abated.Despite a negative binary, CellD
Stocks To Watch: Earnings Blockbusters And Trump Talks Drug Prices https://seekingalpha.com/article/4164569-stocks-watch-earnings-blockbusters-trump-talks-drug-prices?source=feed Apr 21, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
3 Things In Biotech, April 19: Let's Talk Genito-Urinary Cancer https://seekingalpha.com/article/4164253-3-things-biotech-april-19-talk-genito-urinary-cancer?source=feed_sector_healthcare Apr 20, 2018 - Bristol-Myers keeps the pedal down in renal cancer.AstraZeneca posts signs of life in bladder cancer immunotherapy.Calithera gains fast track in renal cell carcinoma.
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR http://www.zacks.com/stock/news/300053/pharma-stock-roundup-nvs-jnj-q1-sales-earnings-top-mrk-bmy-active-at-aacr?cid=CS-ZC-FT-300053 Apr 20, 2018 - Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer http://www.zacks.com/stock/news/299886/bristol-myers-opdivo-gets-priority-review-for-lung-cancer?cid=CS-ZC-FT-299886 Apr 19, 2018 - The FDA accepts Bristol-Myers Squibb's (BMY) supplemental Biologics License Application and grants priority review for the label expansion of Opdivo to treat patients with small cell lung cancer.

Pages: 123456...93

Page 1>
DeepLinks for Bristol-Myers Squibb Company
BMY - Google Finance https://www.google.com/finance?q=BMY Industry related info and international coverage Summary News
BMY - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BMY Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options